New combo aims to supercharge immune cells against blood cancers
NCT ID NCT05044039
First seen Dec 16, 2025 · Last updated May 14, 2026 · Updated 22 times
Summary
This early-phase study tests whether adding the drug duvelisib after CAR T-cell therapy can help the immune cells stay active longer and reduce side effects like cytokine release syndrome. About 42 adults with non-Hodgkin lymphoma or acute lymphocytic leukemia will take part. The goal is to find a safe dose and see if this approach improves cancer control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.